Overview
Biorem Q3 revenue down 24% yr/yr to C$11.3 mln
EPS for Q3 falls to C$0.07 from C$0.14 last year
Company reports record order backlog of C$71 mln
Outlook
Biorem expects strong revenue and earnings growth over the next 12 months
Company reports record order backlog of C$71 mln as of September 30, 2025
Biorem anticipates continued growth in order bookings
Result Drivers
ORDER BACKLOG - Record order backlog of C$71 mln driven by strong order bookings and strategic product adjustments
REVENUE IMPACT - Revenue decline attributed to customer construction timelines and delivery schedules
OPERATING EXPENSES - Decrease in operating expenses due to lower sales and marketing costs
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
C$11.25 mln
Q3 EPS
C$0.06
Q3 Net Income
C$1.16 mln
Q3 Basic EPS
C$0.07
Q3 Gross Profit
C$3.17 mln
Q3 Operating Expenses
C$1.55 mln
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the environmental services & equipment peer group is "buy"
Wall Street's median 12-month price target for Biorem Inc is C$3.50, about 38.6% above its November 14 closing price of C$2.15
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nCNWpv237a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)